News Releases

- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable hematological safety profile of momelotinib - -...

- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28th – - Jefferies Global Virtual Healthcare Conference at 4:30 p.m. ET on June 3rd - VANCOUVER, May 27, 2020 /CNW/...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity - - Long-term safety profile reinforces lack of...

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th - VANCOUVER, May 7, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug...

- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially affect overall MOMENTUM timelines - - Publications...

- MOMENTUM Phase 3 clinical trial for momelotinib underway, targeting enrolment of 180 patients with myelofibrosis who are symptomatic and anemic - - Publications highlighting durability, safety...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER, Feb. 25, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance with amendment to Purchase Agreement -...

- New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting - - Analyst &...

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th - - Data highlighting decreased transfusion requirements for patients treated with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen - - Targeting enrollment of 180 symptomatic...

- "Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 - VANCOUVER, Nov. 14, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug...

- Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra - - Amendments become effective upon Sierra Oncology closing a qualified financing - VANCOUVER, Nov. 7,...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...

- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated...

- MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 - VANCOUVER, Nov. 4, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on...

- Sierra preparing to launch the MOMENTUM Phase 3 myelofibrosis clinical trial expected in Q4 2019 - - Exploring non-dilutive options to support future continued development of DDR portfolio -...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- Corporate prioritization of portfolio to focus resources on advancement of momelotinib - - Exploring non-dilutive options to support future continued development of SRA737 and SRA141 -...

- Fast Track designation highlights the potential for momelotinib to address the significant unmet needs of patients with Intermediate/High-Risk myelofibrosis who have previously received a JAK...

- MOMENTUM Phase 3 clinical trial planned for launch in Q4 2019; topline efficacy data anticipated in Q4 2021 – - World renowned myelofibrosis expert Dr. Srdan Verstovsek named Chief...

- Sierra management and distinguished oncologists Professor Johann de Bono and Dr. Rebecca Kristeleit discuss clinical findings and possible next steps for SRA737 - - Sierra reported SRA737...

- Sierra reports 30% response rate for SRA737+LDG in anogenital cancer - - Anti-cancer activity demonstrated across multiple indications and genetic contexts in preliminary Phase 1/2 data...

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd...

Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /CNW/ - Sierra...

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA),...

- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung...

- Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019 - VANCOUVER, March 5, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER, Feb. 28, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...

- Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small...

- "Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston - VANCOUVER, Jan. 23, 2019 /CNW/ - Sierra Oncology, Inc....

- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks - - Data from...

- SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC) – - Activates immune signaling STING pathway - - Data reported at the AACR Conference on Tumor Immunology and...

- Call to include Dr. Srdan Verstovsek and will discuss emerging clinical data demonstrating momelotinib's unique anemia benefit in patients with myelofibrosis - VANCOUVER, Nov. 27, 2018 /CNW/ -...

- SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models - - PDX models were...

- Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models - VANCOUVER, Nov. 13, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq:...

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 - VANCOUVER, Nov. 8, 2018 /CNW/ - Sierra...

- "Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018 - VANCOUVER, Nov. 7, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug...

– Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of action for momelotinib's anemia benefit in myelofibrosis – – 34% of patients achieved RBC...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology...

- Up to $15 million available in three $5 million tranches; additional $25 million potentially available - VANCOUVER, Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage...

- More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients - - Demonstrated meaningful anemia-related...

- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...